D. E. Shaw & Co., Inc. - NEUROCRINE BIOSCIENCES INC ownership

NEUROCRINE BIOSCIENCES INC's ticker is and the CUSIP is 64125CAD1. A total of 44 filers reported holding NEUROCRINE BIOSCIENCES INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.

Quarter-by-quarter ownership
D. E. Shaw & Co., Inc. ownership history of NEUROCRINE BIOSCIENCES INC
ValueSharesWeighting
Q3 2023$21,373,197
+572.8%
14,351,000
+474.0%
0.02%
+633.3%
Q2 2023$3,176,523
-5.9%
2,500,0000.0%0.00%
-25.0%
Q1 2023$3,376,802
-14.9%
2,500,0000.0%0.00%0.0%
Q4 2022$3,970,192
+12.2%
2,500,0000.0%0.00%0.0%
Q3 2022$3,540,000
+7.0%
2,500,0000.0%0.00%0.0%
Q2 2022$3,308,000
-93.5%
2,500,000
-93.5%
0.00%
-91.7%
Q1 2022$50,796,000
+4.8%
38,635,0000.0%0.05%
+20.0%
Q4 2021$48,457,000
-6.1%
38,635,0000.0%0.04%
-14.9%
Q3 2021$51,580,000
-0.9%
38,635,000
-1.6%
0.05%
+4.4%
Q2 2021$52,046,000
+667.0%
39,270,000
+685.4%
0.04%
+542.9%
Q1 2021$6,786,000
-50.8%
5,000,000
-50.0%
0.01%
-50.0%
Q3 2020$13,805,00010,000,0000.01%
Other shareholders
NEUROCRINE BIOSCIENCES INC shareholders Q1 2022
NameSharesValueWeighting ↓
Mint Tower Capital Management B.V. 4,000,000$5,539,0000.72%
SHENKMAN CAPITAL MANAGEMENT INC 4,369,000$6,113,0000.64%
Context Capital Management, LLC 3,000,000$4,169,0000.57%
CSS LLC/IL 4,527,000$6,272,0000.24%
MACKAY SHIELDS LLC 22,388,000$31,068,0000.21%
ADVENT CAPITAL MANAGEMENT /DE/ 5,931,000$8,177,0000.17%
Calamos Advisors LLC 21,268,000$29,654,0000.17%
PALISADE CAPITAL MANAGEMENT, LP 3,600,000$4,986,0000.13%
LOOMIS SAYLES & CO L P 603,276$57,824,0000.08%
Teton Advisors, Inc. 337,000$470,0000.07%
View complete list of NEUROCRINE BIOSCIENCES INC shareholders